Biodistribution and pharmacokinetics of vanadium following intraperitoneal administration of vanadocene dichloride to mice

Jeffrey H. Toney, M. Satya Murthy, Tobin J Marks

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The biodistribution and pharmacokinetics of vanadium following i.p. administration of vanadocene dichloride (VDC), a representative of a new class of organometallic anticancer agents, is reported for Strain A mice. A convenient flameless atomic absorption spectroscopic assay is described and is used to determine kinetic profiles for vanadium in blood, kidney, liver, small intestine and brain tissue for times up to 24 h after administration. For a VDC dose of 80 mg/kg, vanadium concentration decreases rapidly from both the blood and small intestine, and the data can be fit to a phenomenological exponential function (blood: t 1 2 = 118 ± 43 min; small intestine: t 1 2(α) = 18.10 ± 0.14 min, t 1 2(β) = 341 ± 45 min). In contrast, vanadium accumulates in both the kidney and liver up to a maximal concentration (1.12 ± 0.06 mM and 0.56 ± 0.06 mM after 12 and 8 h, respectively), and is then excreted with estimated half-lives of 7.9 ± 0.7 and 12.1 ± 0.1 h, respectively. No detectable levels of vanadium are found in the brain tissue over the temporal course of the experiment. These results are compared to previous mammalian studies with cis-dichlorodiammineplatinum(II) (CDDP) and related 'second generation' platinum derivatives; there are both qualitative similarities between the vanadium and platinum systems as well as important quantitative differences.

Original languageEnglish
Pages (from-to)45-54
Number of pages10
JournalChemico-Biological Interactions
Volume56
Issue number1
DOIs
Publication statusPublished - Dec 17 1985

Fingerprint

Vanadium
Pharmacokinetics
Small Intestine
Blood
Platinum
Liver
Brain
Tissue
Kidney
Exponential functions
Organometallics
Antineoplastic Agents
Cisplatin
vanadocene dichloride
Assays
Derivatives
Kinetics
Experiments

Keywords

  • Vanadocene dichloride - Biodistribution - Pharmacokinetics - Anti-tumor agent - Mice

ASJC Scopus subject areas

  • Toxicology

Cite this

Biodistribution and pharmacokinetics of vanadium following intraperitoneal administration of vanadocene dichloride to mice. / Toney, Jeffrey H.; Murthy, M. Satya; Marks, Tobin J.

In: Chemico-Biological Interactions, Vol. 56, No. 1, 17.12.1985, p. 45-54.

Research output: Contribution to journalArticle

@article{3d7c78d606f4427abfd3def49aa3b11e,
title = "Biodistribution and pharmacokinetics of vanadium following intraperitoneal administration of vanadocene dichloride to mice",
abstract = "The biodistribution and pharmacokinetics of vanadium following i.p. administration of vanadocene dichloride (VDC), a representative of a new class of organometallic anticancer agents, is reported for Strain A mice. A convenient flameless atomic absorption spectroscopic assay is described and is used to determine kinetic profiles for vanadium in blood, kidney, liver, small intestine and brain tissue for times up to 24 h after administration. For a VDC dose of 80 mg/kg, vanadium concentration decreases rapidly from both the blood and small intestine, and the data can be fit to a phenomenological exponential function (blood: t 1 2 = 118 ± 43 min; small intestine: t 1 2(α) = 18.10 ± 0.14 min, t 1 2(β) = 341 ± 45 min). In contrast, vanadium accumulates in both the kidney and liver up to a maximal concentration (1.12 ± 0.06 mM and 0.56 ± 0.06 mM after 12 and 8 h, respectively), and is then excreted with estimated half-lives of 7.9 ± 0.7 and 12.1 ± 0.1 h, respectively. No detectable levels of vanadium are found in the brain tissue over the temporal course of the experiment. These results are compared to previous mammalian studies with cis-dichlorodiammineplatinum(II) (CDDP) and related 'second generation' platinum derivatives; there are both qualitative similarities between the vanadium and platinum systems as well as important quantitative differences.",
keywords = "Vanadocene dichloride - Biodistribution - Pharmacokinetics - Anti-tumor agent - Mice",
author = "Toney, {Jeffrey H.} and Murthy, {M. Satya} and Marks, {Tobin J}",
year = "1985",
month = "12",
day = "17",
doi = "10.1016/0009-2797(85)90038-9",
language = "English",
volume = "56",
pages = "45--54",
journal = "Chemico-Biological Interactions",
issn = "0009-2797",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Biodistribution and pharmacokinetics of vanadium following intraperitoneal administration of vanadocene dichloride to mice

AU - Toney, Jeffrey H.

AU - Murthy, M. Satya

AU - Marks, Tobin J

PY - 1985/12/17

Y1 - 1985/12/17

N2 - The biodistribution and pharmacokinetics of vanadium following i.p. administration of vanadocene dichloride (VDC), a representative of a new class of organometallic anticancer agents, is reported for Strain A mice. A convenient flameless atomic absorption spectroscopic assay is described and is used to determine kinetic profiles for vanadium in blood, kidney, liver, small intestine and brain tissue for times up to 24 h after administration. For a VDC dose of 80 mg/kg, vanadium concentration decreases rapidly from both the blood and small intestine, and the data can be fit to a phenomenological exponential function (blood: t 1 2 = 118 ± 43 min; small intestine: t 1 2(α) = 18.10 ± 0.14 min, t 1 2(β) = 341 ± 45 min). In contrast, vanadium accumulates in both the kidney and liver up to a maximal concentration (1.12 ± 0.06 mM and 0.56 ± 0.06 mM after 12 and 8 h, respectively), and is then excreted with estimated half-lives of 7.9 ± 0.7 and 12.1 ± 0.1 h, respectively. No detectable levels of vanadium are found in the brain tissue over the temporal course of the experiment. These results are compared to previous mammalian studies with cis-dichlorodiammineplatinum(II) (CDDP) and related 'second generation' platinum derivatives; there are both qualitative similarities between the vanadium and platinum systems as well as important quantitative differences.

AB - The biodistribution and pharmacokinetics of vanadium following i.p. administration of vanadocene dichloride (VDC), a representative of a new class of organometallic anticancer agents, is reported for Strain A mice. A convenient flameless atomic absorption spectroscopic assay is described and is used to determine kinetic profiles for vanadium in blood, kidney, liver, small intestine and brain tissue for times up to 24 h after administration. For a VDC dose of 80 mg/kg, vanadium concentration decreases rapidly from both the blood and small intestine, and the data can be fit to a phenomenological exponential function (blood: t 1 2 = 118 ± 43 min; small intestine: t 1 2(α) = 18.10 ± 0.14 min, t 1 2(β) = 341 ± 45 min). In contrast, vanadium accumulates in both the kidney and liver up to a maximal concentration (1.12 ± 0.06 mM and 0.56 ± 0.06 mM after 12 and 8 h, respectively), and is then excreted with estimated half-lives of 7.9 ± 0.7 and 12.1 ± 0.1 h, respectively. No detectable levels of vanadium are found in the brain tissue over the temporal course of the experiment. These results are compared to previous mammalian studies with cis-dichlorodiammineplatinum(II) (CDDP) and related 'second generation' platinum derivatives; there are both qualitative similarities between the vanadium and platinum systems as well as important quantitative differences.

KW - Vanadocene dichloride - Biodistribution - Pharmacokinetics - Anti-tumor agent - Mice

UR - http://www.scopus.com/inward/record.url?scp=0022405633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022405633&partnerID=8YFLogxK

U2 - 10.1016/0009-2797(85)90038-9

DO - 10.1016/0009-2797(85)90038-9

M3 - Article

VL - 56

SP - 45

EP - 54

JO - Chemico-Biological Interactions

JF - Chemico-Biological Interactions

SN - 0009-2797

IS - 1

ER -